Eiger BioPharmaceuticals Announces Presentations at Upcoming HEP DART 2021 Meeting

PALO ALTO, Calif.: PALO ALTO, Calif., Dec. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that the 24th Biennial HEP DART 2021 Frontiers in...

Click to view original post